7 mars 2023

Published Date: 10 Mar 2023

Today's top stories include: Nine-year cap to complete MBBS, elective-based credits offered in NMC letter Students enrolled in...

Read Full News

Latest News

CT-Quantified Plaque Volume May Predict CAD

Plaque burden predicts major adverse cardiac events, independent of other risk factors.

EMA Rejects Drugs for Rett Syndrome, Schizophrenia

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.

Resuscitation’s Ethical Dilemma: Rethink Epinephrine Use

Epinephrine improves ROSC in cardiac arrest but does not increase favorable neurologic recovery, raising ethical and guideline questions for clinicians.

Bariatric Surgery Beats GLP-1s for Heart Protection in T2D

A meta-analysis of 11 studies involving over 19,000 patients with T2D and obesity shows that bariatric surgery provides greater cardiovascular protection and mortality reduction than GLP-1 drugs.

Tenecteplase May Help Stroke Recovery Past 4.5-Hour Window

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

How Leptin Became the Sexiest Thing in Science (Again)

Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug cocktails to novel treatments for rare diseases and anorexia.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

Plaque burden predicts major adverse cardiac events, independent of other risk factors.

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.

Epinephrine improves ROSC in cardiac arrest but does not increase favorable neurologic recovery, raising ethical and guideline questions for clinicians.

A meta-analysis of 11 studies involving over 19,000 patients with T2D and obesity shows that bariatric surgery provides greater cardiovascular protection and mortality reduction than GLP-1 drugs.

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug cocktails to novel treatments for rare diseases and anorexia.

News All Time

AI Assistant Offers Promise for Patients After HFrEF

A virtual assistant powered by AI supervised by a cardiologist can offer guideline-directed medical therapy optimization after hospitalization for heart failure with reduced ejection fraction.

TAVR Use Increasing Among Younger, Lower-Risk Patients

Once reserved for very high-risk patients, the use of transcatheter aortic valve replacement in low-risk cases has increased since 2012. Low-risk patients now make up over one third of TAVR procedures.

Combo Pill for Treating Hypertension Shows Positive Results

A low-dose, single-pill combination proved to be as effective as — and in some cases, superior to — standard-dose monotherapy for treating hypertension.

Is There a Link Between Elevated BAA & All-Cause Mortality?

Biological age acceleration, independently tied to higher all-cause mortality in patients with moderate-to-severe aortic valve stenosis, showed promise as a prognostic marker.

New Risk Model Predicts Low-Risk Surgery After TAVR

Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps perfect treatment for a growing patient population.

Early HF Risk Does Not Always Worsen, Can Improve Over Time

Many people at risk for heart failure remain stable over time, some worsen, but others improve as well. Blood tests and heart scans can help identify who is most likely to need hospital care.

Which Drugs Turn Risky When Temperatures Soar?

As the planet warms, common medications such as GLP-1s and diuretics can turn a heatwave into a medical emergency, yet many physicians feel unequipped to manage the risk.

Which Type of Prostate Cancer ADT Is Safer for the Heart?

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

Long-Term Air Pollution Exposure Tied to Increased AD Risk

An analysis of nearly 28 million Medicare beneficiaries indicates that long-term exposure to air pollution is a risk factor for Alzheimer’s Disease, especially in those with a history of stroke.

Deepfakes Target NutriScore Co-Developer Serge Hergberg

AI generated videos misuse a French physician’s name and voice to spread false nutrition claims, prompting a criminal complaint and scrutiny of platform safeguards.

PREVENT Calculator Underestimates CVD Risk in Some Adults

A new study raises concerns that the PREVENT calculator may underestimate cardiovascular risk in some young adult populations.

ACC: Don’t Mandate ECG Screening for Athletes

ECG screening for athletes finds more cardiovascular problems, but US states should not require it due to potential downsides, ACC says.

Exercise May Mitigate Risk for Preeclampsia in Pregnancy

Regular aerobic exercise between pregnancies is linked to improved heart health and a reduced risk for preeclampsia recurring in a subsequent pregnancy.

Bariatric Surgery Tied to Early Benefits in MASLD

Bariatric surgery is linked to notable reductions in hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.

Updated HEART Score Enhances CAD Prediction Accuracy of CCTA

Integrating male sex, RBBB, and haemoglobin and glucose levels into the HEART score improves its ability to predict significant coronary artery disease on CCTA in the emergency department setting.

Cold Alerts Backed by New Mortality Data

New monitoring shows vulnerability to cold weather in England may be increasing compared with previous years.

Recommended News For You

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Mezigdomide Combinations Show Promise in Multiple Myeloma

More nonsmokers are getting lung cancer: Oncologist explains why

The most precise research tools for the deadliest blood cancer have been developed.

Recommended Articles For You

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing 

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options  

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025 

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

2.

A new theranostic drug targets different cancer types.

3.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

4.

Investigations may result in novel combination therapies for early-stage lung cancers.

5.

A better option for mild to moderate depression?

1.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

2.

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression

3.

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma

4.

Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma

5.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XVI

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot